Sadly no assurance from management. No direction where the company is going and what has been taken place other then afrezza is back under MNKD control.
With all due respect, how could you think it wouldn't pull back?
They don't have a sales force (are you anticipating an internet sales/marketing campaign??) and they haven't announced a plan to move this drug to patients, educate doctors, or partner with another company who can possibly make that happen. They said they were happy to have it back,....but there is nothing positive about the 4/5/16 announcement.
Market Data 
Markets 
AI
